医学临床研究
醫學臨床研究
의학림상연구
JOURNAL OF CLINICAL RESEARCH
2014年
6期
1065-1067
,共3页
陈愔音%梁玉梅%杨伊雅%陈莹%施文建
陳愔音%樑玉梅%楊伊雅%陳瑩%施文建
진음음%량옥매%양이아%진형%시문건
腹膜透析,持续不卧床%甲状旁腺功能亢进症,继发性%灌流%骨化醇类/投药和剂量
腹膜透析,持續不臥床%甲狀徬腺功能亢進癥,繼髮性%灌流%骨化醇類/投藥和劑量
복막투석,지속불와상%갑상방선공능항진증,계발성%관류%골화순류/투약화제량
Peritoneal Dialysis,Continuous Ambulatory%Hyperparathyroidism,Secondary%Perfu-sion%Ergocalciferols/AD
【目的】评价持续性非卧床腹膜透析(CAPD)合并重度继发性甲状旁腺功能亢进症(SHPT)患者行阿法骨化醇胶囊(阿法迪三)冲击联合血液灌流(HP)治疗的疗效与安全性。【方法】收集本院 CAPD合并重度 SHPT患者37例。随机分为阿法迪三冲击联合 HP治疗组(A组,19例)和阿法迪三冲击治疗组(B组,18例)。两组药物起始剂量均为每次2~4μg,2次/周。A组同时血灌治疗,1次/周,共治疗3周。随访6月。比较两组治疗前后甲状旁腺激素(iPTH)值,临床症状及心脏瓣膜钙化情况。【结果】①治疗后,联合治疗组iPTH达标率、症状缓解率明显高于单独冲击组,且两组相比较差异有显著性(P<0.05)。②随访6个月, A组患者心脏瓣膜钙化率低于B组(73.6% vs 83.3%,P<0.05)。iPTH 达标率 A组高于 B组(94.7% vs 77.8%,P<0.05)。③A组治疗耐受性良好,无一例严重不良反应。B组中3例因高钙高磷血症中断阿法迪三治疗。【结论】合并重度 SHPT的CAPD患者,阿法迪三冲击联合 HP治疗较之单纯阿法迪三冲击具有更好的疗效及耐受性。
【目的】評價持續性非臥床腹膜透析(CAPD)閤併重度繼髮性甲狀徬腺功能亢進癥(SHPT)患者行阿法骨化醇膠囊(阿法迪三)遲擊聯閤血液灌流(HP)治療的療效與安全性。【方法】收集本院 CAPD閤併重度 SHPT患者37例。隨機分為阿法迪三遲擊聯閤 HP治療組(A組,19例)和阿法迪三遲擊治療組(B組,18例)。兩組藥物起始劑量均為每次2~4μg,2次/週。A組同時血灌治療,1次/週,共治療3週。隨訪6月。比較兩組治療前後甲狀徬腺激素(iPTH)值,臨床癥狀及心髒瓣膜鈣化情況。【結果】①治療後,聯閤治療組iPTH達標率、癥狀緩解率明顯高于單獨遲擊組,且兩組相比較差異有顯著性(P<0.05)。②隨訪6箇月, A組患者心髒瓣膜鈣化率低于B組(73.6% vs 83.3%,P<0.05)。iPTH 達標率 A組高于 B組(94.7% vs 77.8%,P<0.05)。③A組治療耐受性良好,無一例嚴重不良反應。B組中3例因高鈣高燐血癥中斷阿法迪三治療。【結論】閤併重度 SHPT的CAPD患者,阿法迪三遲擊聯閤 HP治療較之單純阿法迪三遲擊具有更好的療效及耐受性。
【목적】평개지속성비와상복막투석(CAPD)합병중도계발성갑상방선공능항진증(SHPT)환자행아법골화순효낭(아법적삼)충격연합혈액관류(HP)치료적료효여안전성。【방법】수집본원 CAPD합병중도 SHPT환자37례。수궤분위아법적삼충격연합 HP치료조(A조,19례)화아법적삼충격치료조(B조,18례)。량조약물기시제량균위매차2~4μg,2차/주。A조동시혈관치료,1차/주,공치료3주。수방6월。비교량조치료전후갑상방선격소(iPTH)치,림상증상급심장판막개화정황。【결과】①치료후,연합치료조iPTH체표솔、증상완해솔명현고우단독충격조,차량조상비교차이유현저성(P<0.05)。②수방6개월, A조환자심장판막개화솔저우B조(73.6% vs 83.3%,P<0.05)。iPTH 체표솔 A조고우 B조(94.7% vs 77.8%,P<0.05)。③A조치료내수성량호,무일례엄중불량반응。B조중3례인고개고린혈증중단아법적삼치료。【결론】합병중도 SHPT적CAPD환자,아법적삼충격연합 HP치료교지단순아법적삼충격구유경호적료효급내수성。
[Objective]To evaluate the efficacy and safety of alfacalcidol[1a-(OH)-D3 ]capsule pulse ther-apy combined with hemoperfusion(HP)for the treatment of continuous ambulatory peritoneal dialysis(CAPD) patients with severe secondary hyperparathyroidism(SHPT).[Methods]Totally 37 CAPD patients with severe SHPT were collected and randomly divided into alfacalcidol pulse therapy combined with HP treatment group (group A,n=19)and alfacalcidol pulse therapy group(group B,n=18).The drug initial dose of two groups was 2~4μg twice a week.Group A simultaneously received HP treatment once a week for 3 weeks.All pa-tients were followed up for 6 months.Immunoreactive parathyroid hormone(iPTH)level,clinical symptoms and cardiac valve calcification before and after treatment were compared.[Results]After treatment,the stand-ard reaching rate of iPTH and symptomatic relief rate in combination group were obviously higher than those in single pulse therapy group,and there was significant difference(P<0.05).After 6 month of follow up,car-diac valve calcification rate in group A was lower than that in group B(73.6% vs.83.3%,P<0.05),while the standard reaching rate of iPTH in group A was higher than that in group B(94.7% vs.77.8%,P <0.05).In group A,the tolerance was good and none had severe side reaction.In group B,3 patients discon-tinued alfacalcidol therapy due to hypercalcemia and hyperphosphatemia.[Conclusion]Alfacalcidol pulse ther-apy combined with HP for the treatment of CAPD patients with severe SHPT has better efficacy and tolerance than single alfacalcidol pulse therapy.